Tumor carbohydrate antigens and strategies to develop cancer vaccines and drugs
暂无分享,去创建一个
Craig Meyers | Qin Pan | C. Meyers | Min Liu | F. Luo | Xiao-lian Zhang | Xiao-Lian Zhang | Min Liu | Fengling Luo | Qin Pan
[1] C. Leclerc,et al. Tn Glycosylation of the MUC6 Protein Modulates Its Immunogenicity and Promotes the Induction of Th17-biased T Cell Responses* , 2010, The Journal of Biological Chemistry.
[2] R. Dwek,et al. Altered glycosylation of proteins in cancer: what is the potential for new anti-tumour strategies. , 2008, Anti-cancer agents in medicinal chemistry.
[3] T. Seyfried,et al. N -butyldeoxynojirimycin reduces growth and ganglioside content of experimental mouse brain tumours , 2001, British Journal of Cancer.
[4] J. Taylor‐Papadimitriou,et al. The ST6GalNAc-I Sialyltransferase Localizes throughout the Golgi and Is Responsible for the Synthesis of the Tumor-associated Sialyl-Tn O-Glycan in Human Breast Cancer* , 2006, Journal of Biological Chemistry.
[5] T. Honjo,et al. Molecular mechanism of class switch recombination: linkage with somatic hypermutation. , 2002, Annual review of immunology.
[6] M. Wolfert,et al. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine , 2011, Proceedings of the National Academy of Sciences.
[7] J. Wolchok,et al. Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. , 2006, The Journal of clinical investigation.
[8] M. Frank,et al. Comprehensive modeling and functional analysis of Toll‐like receptor ligand‐recognition domains , 2010, Protein science : a publication of the Protein Society.
[9] M. Wolfert,et al. Robust immune responses elicited by a fully synthetic three-component vaccine. , 2007, Nature chemical biology.
[10] Lai-Xi Wang,et al. Toward a carbohydrate-based HIV-1 vaccine: synthesis and immunological studies of oligomannose-containing glycoconjugates. , 2006, Bioconjugate chemistry.
[11] Xiao-lian Zhang,et al. Knockdown of Mgat5 Inhibits Breast Cancer Cell Growth with Activation of CD4+ T Cells and Macrophages1 , 2008, The Journal of Immunology.
[12] W. Engström,et al. The effects of glycosylation inhibitors on the proliferation of a Wilms tumour cell line. , 2000, Anticancer research.
[13] Qian Wan,et al. From synthesis to biologics: preclinical data on a chemistry derived anticancer vaccine. , 2009, Journal of the American Chemical Society.
[14] P. Linton,et al. Use of CD40L immunoconjugates to overcome the defective immune response to vaccines for infections and cancer in the aged , 2009, Cancer Immunology, Immunotherapy.
[15] T. Oyama,et al. Low expression of polypeptide GalNAc N-acetylgalactosaminyl transferase-3 in lung adenocarcinoma: impact on poor prognosis and early recurrence , 2004, British Journal of Cancer.
[16] C. Leclerc,et al. A fully synthetic immunogen carrying a carcinoma-associated carbohydrate for active specific immunotherapy. , 1999, Cancer research.
[17] T. Gallagher,et al. Action of a library of O-glycosylation inhibitors on the growth of human colorectal cancer cells in culture. , 2005, Biochemical Society transactions.
[18] G. Boons,et al. Immunotherapy for cancer: synthetic carbohydrate-based vaccines. , 2009, Chemical communications.
[19] R. Tiwari,et al. Sialic acid content of tissue-specific gp96 and its potential role in modulating gp96-macrophage interactions. , 2009, Glycobiology.
[20] T. Michaelsen,et al. The four mouse IgG isotypes differ extensively in bactericidal and opsonophagocytic activity when reacting with the P1.16 epitope on the outer membrane PorA protein of Neisseria meningitidis , 2004, Scandinavian journal of immunology.
[21] Kate Rittenhouse-Olson,et al. Cancer vaccines and carbohydrate epitopes. , 2011, Vaccine.
[22] Ingo Müller,et al. Dendritic cells: functional aspects of glycosylation and lectins. , 2009, Human immunology.
[23] M. Pierce,et al. Knockdown of GnT-Va expression inhibits ligand-induced downregulation of the epidermal growth factor receptor and intracellular signaling by inhibiting receptor endocytosis. , 2009, Glycobiology.
[24] A. Hoffmann‐Röder,et al. Fluorinated glycosyl amino acids for mucin-like glycopeptide antigen analogues. , 2010, Chemistry.
[25] Lai-Xi Wang,et al. Enhanced immune recognition of cryptic glycan markers in human tumors. , 2009, Cancer research.
[26] A. Dalgleish,et al. Overview of Tumor Cell–Based Vaccines , 2006, International reviews of immunology.
[27] G. Springer. Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy , 1997, Journal of Molecular Medicine.
[28] C. Leclerc,et al. Glycosidic Tn-based vaccines targeting dermal dendritic cells favor germinal center B-cell development and potent antibody response in the absence of adjuvant. , 2010, Blood.
[29] S. Danishefsky,et al. Synthetic carbohydrate-based anticancer vaccines: the Memorial Sloan-Kettering experience , 2009, Expert review of vaccines.
[30] Christopher Jones,et al. Vaccines based on the cell surface carbohydrates of pathogenic bacteria. , 2005, Anais da Academia Brasileira de Ciencias.
[31] A. Passaniti,et al. The α-Glucosidase I Inhibitor Castanospermine Alters Endothelial Cell Glycosylation, Prevents Angiogenesis, and Inhibits Tumor Growth , 1995 .
[32] P. Vogel,et al. Glycosidase inhibitors as potential HIV entry inhibitors? , 2004, Current drug metabolism.
[33] R. Dwek,et al. Evidence that N-linked glycosylation is necessary for hepatitis B virus secretion. , 1995, Virology.
[34] D. Godson,et al. The effectiveness and limitations of immune memory: understanding protective immune responses. , 2003, International journal for parasitology.
[35] D. Bundle. A carbohydrate vaccine exceeds the sum of its parts. , 2007, Nature chemical biology.
[36] G. Boons,et al. The immunogenicity of the tumor-associated antigen Lewis(y) may be suppressed by a bifunctional cross-linker required for coupling to a carrier protein. , 2004, Chemistry.
[37] O. Finn,et al. Differential expression of MUC1 on transfected cell lines influences its recognition by MUC1 specific T cells , 1996, Glycoconjugate Journal.
[38] D. Hicks,et al. Prospects in NSAID-derived chemoprevention of colorectal cancer. , 2005, Biochemical Society transactions.
[39] Lai-Xi Wang,et al. Antibody recognition of a unique tumor-specific glycopeptide antigen , 2010, Proceedings of the National Academy of Sciences.
[40] A. Varki,et al. Biological roles of oligosaccharides: all of the theories are correct , 1993, Glycobiology.
[41] E. Fischer,et al. NY‐ESO‐1 protein glycosylated by yeast induces enhanced immune responses , 2010, Yeast.
[42] D. Weiner,et al. Priming characteristics of peptide mimotopes of carbohydrate antigens. , 2003, Vaccine.
[43] Pin Wang,et al. Production of lentiviral vectors with enhanced efficiency to target dendritic cells by attenuating mannosidase activity of mammalian cells , 2011, Journal of biological engineering.
[44] F. Auzanneau,et al. Synthesis of a BSA-Le(x) glycoconjugate and recognition of Le(x) analogues by the anti-Le(x) monoclonal antibody SH1: the identification of a non-cross reactive analogue. , 2010, Bioorganic & medicinal chemistry.
[45] R. Weichselbaum,et al. MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer. , 2009, Cancer research.
[46] Mahadeo A. Sukhai,et al. Suppression of Cancer Progression by MGAT1 shRNA Knockdown , 2012, PloS one.
[47] P. Altevogt,et al. Different expression levels of alpha3/4 fucosyltransferases and Lewis determinants in ovarian carcinoma tissues and cell lines. , 2006, International journal of oncology.
[48] S. Turanli,et al. Prognostic role of serum cancer antigen 15-3 in breast cancer patients with isolated bone metastases , 2010, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.
[49] M. Dwek,et al. Cell surface glycan-lectin interactions in tumor metastasis. , 2011, Acta histochemica.
[50] J. Ravetch,et al. Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding , 2005, Science.